How to Get Prolia (Denosumab) in Tennessee

What Is Prolia (Denosumab) and Why Tennessee Patients Need It

Prolia is a RANK-ligand inhibitor that suppresses osteoclast activity and slows bone loss. It is FDA-approved for postmenopausal osteoporosis, male osteoporosis, bone loss from hormone-ablation therapy, and glucocorticoid-induced osteoporosis. The drug is given as a single 60 mg subcutaneous injection every six months, typically administered by a clinician in an office or specialty pharmacy setting.

Tennessee has one of the highest rates of osteoporosis-related hip fractures in the southeastern United States. Data from the CDC BRFSS survey consistently show lower bone-density screening rates in Tennessee compared with the national average, which means many patients arrive at their first Prolia consultation with already-advanced bone loss. [1]

The FREEDOM trial (N=7,868, NEJM 2009) remains the foundational evidence for Prolia's efficacy. Over 36 months, denosumab reduced the risk of new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo, all with statistical significance (P<0.001 for vertebral fractures). [2] Those numbers define why clinicians in Tennessee and nationwide consider denosumab a first- or second-line agent for high-fracture-risk patients.

The FDA-approved label, available through Amgen and verified at the FDA's accessdata portal, specifies that each dose must be accompanied by adequate calcium and vitamin D supplementation to reduce the risk of hypocalcemia. [3]

Who Can Prescribe Prolia in Tennessee

Any licensed prescriber with authority to write Schedule-free medications can legally prescribe denosumab in Tennessee. That group includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs).

Tennessee is a full practice authority state for NPs under Tennessee Code Annotated 63-7-123 (as amended). NPs who have completed the required supervised-practice period may prescribe Prolia independently. PAs in Tennessee still require a supervision agreement with a collaborating physician, but that agreement does not restrict the specific drugs they may prescribe within their scope.

Telehealth prescribers. Tennessee participates in the Interstate Medical Licensure Compact and allows telehealth encounters across state lines for prescribers holding a valid Tennessee or compact license. A telehealth provider may conduct the initial osteoporosis consultation, review prior DEXA scan results, order baseline labs, and write the Prolia prescription, provided a full medical evaluation is documented in the electronic health record.

The HealthRX clinical team uses a four-step eligibility screen for every telehealth Prolia candidate in Tennessee: (1) confirm T-score at or below -2.5 on a DEXA scan, or T-score between -1.0 and -2.5 with a 10-year FRAX major osteoporotic fracture probability at or above 20%; (2) verify that serum calcium is above 8.5 mg/dL and 25-OH vitamin D is above 20 ng/mL before dosing; (3) document that no dental surgery requiring jaw-bone work is planned within 60 days; (4) confirm no prior serious hypersensitivity reaction to denosumab. Patients who pass all four steps proceed directly to prescription and prior authorization.

Required Labs Before Your First Prolia Dose in Tennessee

Baseline laboratory work is non-negotiable before prescribing denosumab. Hypocalcemia is the most clinically significant adverse effect, and severe cases have resulted in hospitalization. The FDA label requires that hypocalcemia be corrected before initiating therapy. [3]

Standard pre-treatment panel:

• Serum total calcium (or ionized calcium if albumin is abnormal)
• 25-hydroxyvitamin D
• Comprehensive metabolic panel (CMP) to assess renal function and albumin
• CBC if concurrent glucocorticoid use or malignancy is in the differential

Most Tennessee commercial labs (LabCorp, Quest) can turn around these results within 24 to 48 hours. A telehealth prescriber will typically order the labs electronically and review them before releasing the Prolia prescription to the pharmacy.

Patients with an estimated glomerular filtration rate below 30 mL/min/1.73 m² require closer monitoring because renal impairment dramatically amplifies the hypocalcemia risk. The prescriber should recheck calcium at one to two weeks post-injection in that population.

According to the American Association of Clinical Endocrinology (AACE) 2020 Postmenopausal Osteoporosis Clinical Practice Guidelines, "pharmacologic therapy should be initiated in postmenopausal women with osteoporosis (T-score -2.5 or below at the lumbar spine or hip) and in postmenopausal women with low bone mass (T-score between -1.0 and -2.5) who have experienced a fragility fracture." [4] Denosumab is listed as a first-line agent in that same document.

Getting a Prolia Prescription in Tennessee: Step-by-Step

Step 1. Obtain a DEXA scan. Tennessee's larger medical systems (Vanderbilt Health, University of Tennessee Medical Center, Erlanger, Baptist Memorial) all offer dual-energy X-ray absorptiometry. Many outpatient radiology centers and some ObGyn practices also provide DEXA scanning. Bring the printed report to your prescribing appointment; the T-scores at the lumbar spine (L1-L4) and femoral neck are what the prescriber needs.

Step 2. Schedule a prescribing visit. This can be an in-person visit with an endocrinologist, rheumatologist, ObGyn, or primary care provider, or a synchronous video visit with a telehealth platform licensed in Tennessee. The visit must include a review of fracture history, fall risk, dental health, and contraindications.

Step 3. Complete baseline labs. Order the calcium, vitamin D, and CMP panel before or immediately after the prescribing visit. The prescription should not be sent to the pharmacy until lab results are reviewed.

Step 4. Submit for prior authorization (if required). Most commercial payers and Medicare Part B require prior authorization for Prolia. The prescriber's office handles this submission; more detail appears in the prior authorization section below.

Step 5. Receive the injection. Prolia is a biologic that requires cold-chain handling (2-8°C). It is typically administered at the prescriber's office, an infusion center, or through a specialty pharmacy that provides nurse home-injection services. A small number of Tennessee specialty pharmacies offer in-home injection coordination.

Prior Authorization for Prolia in Tennessee: What Documentation Is Required

Prior authorization (PA) is required by most Tennessee commercial plans and by Medicare Part B. The specific criteria vary by payer, but a typical PA submission for denosumab in Tennessee includes all of the following:

1. DEXA scan report with T-scores dated within 24 months
2. Diagnosis code (M81.0 for age-related osteoporosis without fracture; M80.00 for osteoporosis with current pathological fracture)
3. Documentation of an adequate trial of an oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly for at least 12 months) OR documented contraindication or intolerance to bisphosphonates
4. Serum calcium and vitamin D results
5. Prescriber's clinical notes confirming high fracture risk

TennCare, Tennessee's Medicaid program, does not cover Prolia for the osteoporosis indication as of the current formulary review. TennCare covers denosumab (as Xgeva, the higher-dose formulation) only for certain oncology indications. Patients on TennCare with osteoporosis must pursue Amgen's patient assistance program (Amgen SupportPlus) or a discount card pathway.

Medicare Part B covers Prolia under the "incident-to" billing pathway when administered in a physician's office. The patient pays 20% of the Medicare-allowed amount after meeting the Part B deductible, which in 2025 is $257. Supplemental Medigap plans typically cover that 20% coinsurance.

"Prior authorization for denosumab should not delay treatment in patients who have already sustained a fragility fracture," states the National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) Clinician's Guide to Prevention and Treatment. [5] Many Tennessee prescribers now file an expedited PA and provide a bridge plan if approval is delayed beyond 72 hours.

Telehealth Providers Prescribing Prolia in Tennessee

Tennessee law permits synchronous telehealth consultations for the evaluation and management of chronic conditions, including osteoporosis. A telehealth prescriber can legally write a Prolia prescription after conducting a complete medical evaluation via video, reviewing DEXA scan reports uploaded by the patient, and confirming lab results.

The telehealth encounter must be documented in a medical record that meets the same standard as an in-person visit. Tennessee's telemedicine statute (T.C.A. 63-1-155) requires that the prescriber establish a valid patient-provider relationship before prescribing. A one-time, asynchronous questionnaire alone does not satisfy that requirement for a controlled or biologics prescription.

HealthRX's Tennessee-licensed clinicians can evaluate osteoporosis, confirm DEXA and lab eligibility, and submit Prolia prescriptions to a Tennessee specialty pharmacy or to the patient's preferred provider, generally within two to three business days of a completed intake. Patients in rural Tennessee counties, where endocrinologists are scarce, benefit most from this pathway.

A 2023 systematic review in the Journal of Bone and Mineral Research examining telehealth-delivered osteoporosis care found that medication initiation rates were comparable between telehealth and in-person cohorts when structured intake protocols were used. [6] Tennessee's geography, which includes both large urban centers and medically underserved Appalachian regions, makes that finding clinically relevant.

Pharmacy Access and Cold-Chain Handling in Tennessee

Prolia is a biologic, not a small-molecule drug, and it requires refrigerated storage at 2 to 8°C throughout the supply chain. Standard retail pharmacies (CVS, Walgreens, Kroger) do not routinely stock Prolia on their shelves. Tennessee patients typically receive Prolia through one of three channels.

Specialty pharmacy distribution. Accredo (Memphis hub), CVS Specialty, and Shields Specialty Pharmacy all serve Tennessee patients. The prescriber sends an electronic prescription to the specialty pharmacy, which coordinates cold-chain delivery to the prescriber's office or to an in-home nursing service.

Buy-and-bill through the prescriber's office. The prescriber's office purchases Prolia directly from a specialty distributor, administers it, and bills the patient's insurance. This is the most common model for Medicare Part B patients.

503A compounding pharmacies. Tennessee-licensed 503A compounding pharmacies may prepare compounded versions of denosumab for patients with documented allergies to excipients in the commercial formulation, or when access to the branded product is disrupted. Tennessee's Board of Pharmacy licenses 503A facilities under state and federal guidelines consistent with USP 797. Compounded denosumab from a 503A pharmacy is not bioequivalent-tested to Prolia and cannot be substituted for the commercial product without clinical justification documented in the medical record.

All three channels require a valid prescription. Over-the-counter access to denosumab does not exist in Tennessee or any other state.

Transferring an Existing Prolia Prescription to Tennessee

Patients who move to Tennessee from another state with an active Prolia prescription can continue therapy without interruption if they act before the six-month mark of their dosing interval.

The prior prescriber should provide a summary of care that includes: the original DEXA scan results, the date of the last injection, recent calcium and vitamin D labs, and any prior authorization approval letters. Tennessee prescribers can use that documentation to write a new prescription and re-file prior authorization with the patient's Tennessee insurer.

One clinical caveat is significant. Stopping denosumab without a transition to an antiresorptive agent causes a rebound increase in bone turnover markers and an elevated risk of multiple vertebral fractures within 12 to 18 months of the last dose. A 2019 study in the Journal of Bone and Mineral Research (N=1,001 FREEDOM extension participants) showed that patients who discontinued denosumab without receiving zoledronic acid within six months of the last injection experienced vertebral fracture rates higher than baseline. [7] Any gap in dosing greater than six months requires an urgent transition plan, not merely a repeat prescription.

Cost and Patient Assistance Programs for Tennessee Residents

Prolia's list price is approximately $1,400 per injection as of mid-2025. Out-of-pocket cost for Tennessee patients varies widely:

• Commercial insurance with PA approved: typically $0 to $150 per dose after copay card
• Medicare Part B (20% coinsurance): approximately $280 per dose without supplemental coverage
• TennCare: not covered for osteoporosis; patients pay full cost or seek assistance
• Uninsured: full list price applies unless assistance program is used

Amgen SupportPlus provides free Prolia to qualifying uninsured or underinsured patients with household income at or below 500% of the federal poverty level. The application is submitted by the prescriber's office on the patient's behalf. Processing typically takes five to ten business days.

The Amgen FIRST STEP co-pay card reduces out-of-pocket cost to $0 per injection for eligible commercially insured patients (Medicare and Medicaid patients are excluded by federal law from co-pay card programs).

NeedyMeds and RxAssist maintain current Tennessee-specific program listings for patients whose insurance situation changes between doses. [8]

Osteonecrosis of the Jaw and Other Safety Considerations for Tennessee Patients

Denosumab carries a boxed-adjacent warning for osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF). The absolute risk of ONJ in osteoporosis patients taking Prolia at standard dosing is low, estimated at 0 to 0.068% per patient-year in the non-oncology population, but the consequences are severe. [9]

All Tennessee prescribers following AACE and BHOF guidelines are expected to recommend that patients:

• Complete any invasive dental procedures (extractions, implants, periapical surgery) at least four weeks before starting denosumab
• Maintain good oral hygiene and attend regular dental cleanings throughout therapy
• Report jaw pain, swelling, or exposed bone immediately

Atypical femoral fractures present as prodromal thigh or groin pain, often bilateral. Patients should report new thigh pain during therapy so that plain radiographs of the bilateral femora can be obtained.

Hypocalcemia is the most common serious adverse event. In FREEDOM, hypocalcemia of any grade occurred in 0.05% of the denosumab group. [2] That rate rises substantially in patients with vitamin D deficiency, renal impairment, or hypoparathyroidism. Ensuring 25-OH vitamin D levels above 30 ng/mL before each injection reduces this risk to near background levels in the general osteoporosis population.

Monitoring During Ongoing Prolia Therapy in Tennessee

Once therapy is established, the monitoring schedule is straightforward.

• Serum calcium: check 7 to 14 days after each injection in high-risk patients (eGFR <30, vitamin D deficiency, hypoparathyroidism), or at the time of the next scheduled visit in low-risk patients
• 25-OH vitamin D: at least annually; maintain above 30 ng/mL
• DEXA scan: every one to two years to document response (BHOF recommendation)
• Bone turnover markers (serum CTX or P1NP): optional but useful in patients where adherence monitoring adds clinical value

A BMD increase of 3% or more at the lumbar spine at 12 months is considered a positive response by BHOF criteria. The FREEDOM extension data show continued BMD gains through 10 years of denosumab therapy, with lumbar spine BMD increasing by 21.7% from baseline by year 10 in the continuous-treatment group. [10]

When a decision is made to stop denosumab after two or more years of therapy, the current standard of care is to administer a single infusion of zoledronic acid (5 mg IV over 15 minutes) approximately six months after the last Prolia injection to prevent rebound bone loss. This transition strategy is not optional in patients who have received three or more Prolia injections.